SVN-015

About SVN-015

A novel selective serotonin and dopamine reuptake inhibitor (SDRI) for stimulant use disorder (cocaine and methamphetamine use) and major depressive disorder (MDD), discovered through Solvonis’ AI drug discovery programme.

Progress to date

Accepted into the US National Institute on Drug Abuse (NIDA) Addiction Treatment Discovery Program for SUD. Under the programme, NIDA, part of the US National Institutes of Health, will fund and conduct early preclinical evaluation of SVN-015.

Separately, SVN-015 has demonstrated positive preclinical data in antidepressant-like activity, when benchmarked against fluoxetine (Prozac®). This shows potential in supporting MDD patients with inadequate SSRI response.

Strategic significance

Expands pipeline beyond AUD/PTSD into stimulant addictions – where there is major unmet need with no approved drug treatments – and depression, where existing treatments often fail to control symptoms.

Market opportunity

SUD: Around 3.0-3.2 million patients across US, EU5, and Japan. No approved pharmacological treatments; psychosocial interventions only, with limited outcomes.

MDD: Around 21 million patients in the US annually, and between 40 and 44 million adults across the company's seven major markets (US, EU5, and Japan).

Despite widespread SSRI use, many patients fail to achieve adequate symptom control.